The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Morning SOG ... thanks for confirming that ... I think we will get news soon ... have a good day and put your seat belt on ... I think we are about to go on the ride of a lifetime
Mafuta,goodmorning. I believe Sierra are well aware of the worth of the Chk1. In an early statement with regards to funding they stated SRA 737 may prove to be more commercially viable than Momelotinib. Not long afterwards down came the for sale sign.
CHK1 not brilliant on it's own. I would hazard a guess this is due to cancer cells not having a programmed cell death (apoptosis). It is only when chemotherapy or similar is given which kills the cancer cells, that the cancer cells then divide rapidly ( normally mitosis ie splitting into two) and multiply rapidly.
The checkpoint kinase inhibitor prevents regrowth by cycle arrest by TP53 inhibition. TP53 is required in many cancer cell cycles to reproduce. Hence, very effective against many, but not all cancers, when used in combination. Very good ADME too.
Regards
Who knows Sierra could be involved in negotiations and subject to a NDA ... I very much doubt it's been shelved ... Guess we won't know until news get out ...
Luton, I agree. Hiding SRA737 away when knowing the increasing evidence of its efficacy in combination studies is disingenuous to say the least ( some would say criminal) and very misleading to many investors who think that SRA737 is not even part of the Sierra portfolio anymore. It’s been in Dilley’s back pocket for far too long. He needs to extract it now and come cleancome clean , get the combo studies going and start building Sierra into the pharmaceutical company they say it wants to be.
I am as positive as anyone on the potential of 737 but the reality is that Sierra have hardly acknowledged it in any shape or form for a long while now. Too effing long.
Nothing shown at all that they are intending to progress with the trials near term.
It is about time Sierra relinquished the rights.
No last chance , lets have it back and then work towards the best way forward.
After all, on results to date it is a compound in a million.
And it needs to be very soon. The many institutions invested in Sierra were promised fireworks and all they have had to date is a very damp squib. Reflected in the downward trajectory of the share price. Dilley has not got time on his hands so he needs to come up with the plan for SRA 737. It’s now or never.
My thrust is. Bms results were today. And they have announced a co dev deal on their pd1 opdivo (non exclusive). Merck is tomorrow and im half expecting similar for keytruda and 737. If not tomoz. Very soon.
Disappointing that Sierra have made such little progress with something that has so much potential and could be saving lives.
AND 737 is yet only ONE trick this thoroughbred pony has ... Get up and smell the coffee
T2 outstanding as norm, you must be on your wotsits tonight ;)
or even your home brew ;)
Thoth.....amazing find......am I right this person was highly excited about our chk1 drug. And has seem its profile in action?
You are like the Indiana Jones...finding these gems
For the newbies who havent been following this. The lovely and talented triparna sen (md andersen centre. Pd-1 combos (opdivo, keytruda etc). Lung cancer. And our lovely 737
https://ecancer.org/en/video/7768-efficacy-and-immune-correlates-of-the-sra737-plus-ldg-regimen-in-combination-with-anti-pd-l1-in-an-sclc-model
Wow, if she is involved then we will see fireworks.
https://www.biospace.com/article/bridgebio-bristol-myers-squibb-start-clinical-trial-to-treat-advanced-solid-tumors-with-kras-mutations/
Kras. Pd-1 combo. Nsclc. Md anderson centre. All you would need in the name "triparna sen" to have a 737 onlicence slamdunk